Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidant

This article was originally published in The Gray Sheet

Executive Summary

U.S. shipments of the Discovery and Meridian next-generation pacemaker families are scheduled to begin May 5, following receipt of FDA approval April 30, the firm says. Approved via premarket approval application supplement to Guidant's Vigor pacemaker, the device families include single- and dual-chamber models with adaptive-rate pacing and advanced diagnostics. The devices incorporate Quick Start, Quick Check and Quick Notes features, designed to allow clinicians "to easily and quickly perform a comprehensive set of automatic tests and follow-up device operations," and provide a printout summarizing data needed for informed patient management, Guidant explains. The Discovery line also has the ability to store and display "diagnostic-quality atrial and ventricular electrograms simultaneously." The devices debuted in Europe in mid-March

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel